SinoMab BioScience Valuation

Is 3681 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3681 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 3681's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 3681's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3681?

Key metric: As 3681 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 3681. This is calculated by dividing 3681's market cap by their current book value.
What is 3681's PB Ratio?
PB Ratio	4.1x
Book	CN¥276.93m
Market Cap	CN¥1.14b

3681 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	709.9x
Enterprise Value/EBITDA	-7.8x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 3681's PB Ratio compare to its peers?

The above table shows the PB ratio for 3681 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.4x
1167 Jacobio Pharmaceuticals Group	1.2x	n/a	HK$1.2b
2171 CARsgen Therapeutics Holdings	2.4x	24.6%	HK$3.9b
1672 Ascletis Pharma	0.7x	-4.1%	HK$1.7b
9939 Kintor Pharmaceutical	1.1x	25.8%	HK$463.3m
3681 SinoMab BioScience	4.1x	n/a	HK$1.2b

Price-To-Book vs Peers: 3681 is expensive based on its Price-To-Book Ratio (4.1x) compared to the peer average (1.4x).

Price to Book Ratio vs Industry

How does 3681's PB Ratio compare vs other companies in the HK Biotechs Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
2137 Brii Biosciences	0.2x	-7.4%	US$93.93m
2126 JW (Cayman) Therapeutics	0.3x	-1.8%	US$68.60m
6628 Transcenta Holding	0.3x	12.7%	US$40.05m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 3681 is expensive based on its Price-To-Book Ratio (4.1x) compared to the Hong Kong Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is 3681's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3681 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 3681's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Shineway Pharmaceutical Group

HK$6.1b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.13

-3.3%

n/a

3SBio

HK$13.0b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.52

-4.3%

-26.2%

Consun Pharmaceutical Group

HK$6.8b

Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.

1681

HK$8.22

-2.1%

74.9%